31.10.2012 • News

Air Liquide Major Licensor for Petrobras Gas-to-Chemicals Complex in Brazil

Air Liquide is further expanding its footprint in Brazil, establishing a new licensing agreement with Petróleo Brasileiro (Petrobras) in conjunction with its recently awarded contract to Foster Wheeler for a world-scale grassroots gas-to-chemicals complex in Linhares, Espirito Santo State, South-East Brazil, called Complexo Gás-Químico.

Air Liquide is the licensor for the Integrated Unit -- the complex's largest and most integral unit -- which will produce syngas, methanol, ammonia, power and steam. Air Liquide will also furnish fully integrated Basic Engineering Design (BED) and Engineering Services during the execution of the Front End Engineering Design (FEED) as well as technical assistance during the Engineering, Procurement & Construction (EPC) phase through start-up of the complex. The BED/FEED phase is scheduled for completion at the end of 2013.

The complex is expected to produce in excess of one million tons per year of ammonia and urea fertilizers, methanol, acetic acid, plus formic acid and melamine, helping to reduce Brazil's imports of these products.

Air Liquide has been present in Brazil for more than 65 years and continues to expand its investments in the region. Among its investments there, Air Liquide Brazil recently announced contracts with major regional firms: Coca-Cola bottler FEMSA and Suzano Papel e Celulose, investing nearly $90 million (€70 million) to develop the two projects.

 

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read